ADC Biotechnology (ADC BIO) – a specialist ADC contract services company with proprietary conjugation technology designed to overcome process and aggregation challenges during the development of new antibody drug conjugates (ADCs) – announces the signing of a partnership agreement with  multi-disciplined engineering specialists, WHP.

The design, planning and building work commences immediately and will deliver a purpose-built, dual stream facility, which will occupy approximately 60% of the available 6,500m2 space. This deal will support phase 1 of construction, which includes a facility for clinical and small-scale commercial production of ADCs. Further construction activity is planned post January 2019 as the company continues its expansion and adds more capacity for large scale clinical, commercial and potential dosage form production (fill/finish).